Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 4/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 3/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 3/20 | 1.00 |
| ▸ | CA1 | P00915 | 1/20 | 0.72 |
| ▸ | CA2 | P00918 | 1/20 | 0.72 |
| ▸ | CA4 | P22748 | 1/20 | 0.72 |
| ▸ | CA9 | Q16790 | 1/20 | 0.72 |
| ▸ | NT5E | P21589 | 3/20 | 0.67 |
| ▸ | P2RY1 | P47900 | 6/20 | 0.65 |
| ▸ | P2RY11 | Q96G91 | 4/20 | 0.65 |
| ▸ | CD99 | P14209 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7605264 | 0.85 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL6745804 | 0.85 | ADORA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BNT5E | |
| SCHEMBL4451649 | 0.85 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL4451640 | 0.85 | ADORA3 (1.00) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL14201599 | 0.84 | CA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL29737838 | 0.84 | CA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL2489474 | 0.84 | CA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL2489469 | 0.84 | CA1 (1.00) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL8423419 | 0.83 | P2RY1 (0.83) | ADORA3ADORA1ADORA2AADORA2BCA1 | |
| SCHEMBL8423402 | 0.83 | P2RY1 (0.83) | ADORA3ADORA1ADORA2AADORA2BCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183224-B2 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090062314-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-7423144-B2 | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2008-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062314-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA1 2/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.